News About: Pharm. Industry
Mundi Pharma files patent case against Hana Pharm in Korea
Switzerland based Mundi Pharma Laboratories has filed a lawsuit in the Seoul Central District Court on June 30, challenging Hana Pharm's recent launching for marketing the generic versions of Oxycontin (oxycodone HCl)...
Hanmi looking to boost Xenical generic sales
Hanmi Pharm aims to achieve the sales target of Lipidown (orlistat 120 mg) to 10 billion won this year, the company said on July 3.
The company held its Lipidown-promotion campaign where 900 salespersons and TV act...
SK Chemicals to release new gout medication
SK Chemicals announced on July 2 that it received the marketing approval of Febuxostat 80 mg (brand name: Feburic), an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout...
Combined hypertensive medicines market warming up
The domestic market of combined antihypertensive agents is gaining momentum with Korean leading manufacturers who see opportunities in the field.
Novartis Korea has pioneered the field with its Exforge in 2007 and ...
Daewoong, Neomics to develop anticancer drug
Daewoong Pharm has recently signed a memorandum of understanding with Neomics Co., a local biopharmaceutical company, to develop, manufacture and commercialize a novel antitumor drug using AIMP2-DX2, a tumor gene that...
Pharmaceutical output of Dong-A grows 16.6% in 2008
Dong-A Pharm posted 749.5 billion won in pharmaceutical production last year, a 16.6 percent gain from a year earlier.
Hanmi Pharm came in second with 579.6 billion won in drug output. The third player was Daewoong...
Experts advise rational approach on asbestos-contaminated drugs scrap issue
Pharmaceutical experts say the government should adopt more rational approach in dealing with the scrap of recovered drugs blacklisted over harmful talc with asbestos.
The Korea Food and Drug Administration claimed...
Doctors pressed not to receive illegal rebate
There are growing voices against shady deals between pharmaceutical companies and doctors as the Korea Broadcasting System has reported illegal cases of rebate.
So far, not a single doctor has been punished for the...
Additional clinical trial should be necessary during postmarketing surveillance
Drug makers are obligated to conduct the additional clinical trial of a pharmaceutical drug in the period of postmarketing surveillance (PMS), under the newly revised regulation over re-examination of the drug, accord...
Validation procedures for OTC products is compulsory from July 1
The mandatory validation system for OTC products has been implemented from July 1, according to the Korea Food and Drug Administration.
Under the new good manufacturing practice (GMP) rules, OTC makers, who intend...
